Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Immune tolerance induction in development

Erik Berntorp

Blood (2023) 141 (16): 1901–1902.

https://doi.org/10.1182/blood.2022019465

Published: 2023

Journal Articles

Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A

Alexander Solms, Anita Shah, Sara Wiegmann, Maurice Ahsman, Erik Berntorp, Andreas Tiede, MD, Alfonso Iorio, MDPhD, Maria Elisa Mancuso, Tihomir Zhivkov, Toshko Lissitchkov

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136586

Published: 2020

Journal Articles

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Alfonso Iorio, Monika Maas Enriquez, Heinz Delesen, Alexander Solms, Stacy E. Croteau, Erik Berntorp

Blood (2019) 134 (Supplement_1): 3637.

https://doi.org/10.1182/blood-2019-127046

Published: 2019

Journal Articles

Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI)

C. Escuriola Ettingshausen, Erik Berntorp, MD PhD, Yesim Dargaud, MD PhD, Zeynep Gutowski, PhD, Claude Negrier, Anna Pavlova, MD PhD, Johannes Oldenburg

Blood (2018) 132 (Supplement 1): 2482.

https://doi.org/10.1182/blood-2018-99-114408

Published: 2018

Journal Articles

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Blood (2018) 132 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2018-99-113996

Published: 2018

Journal Articles

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Luciano Baronciani, PhD, Flora Peyvandi, MD PhD, Anne Goodeve, PhD, Reinhard Schneppenheim, MDPhD, Zahra Badiee, Mohammad-Reza Baghaipour, Javier Battle, Erik Berntorp, MD PhD, Imre Bodó, MD PhD, Ulrich Budde, MD, Andrea Cairo, PhD, Giancarlo Castaman, Laura Crookes, Jeroen C.J. Eikenboom, MD, Peyman Eshghi, MD, Cosimo Ettorre, MD, Jenny Goudemand, MD PhD, Wolf Hassenpflug, Charles Richard Morris Hay, MDFRCP,FRCPath, Hamid Hoorfar, MD, Mehran Karimi, MD, Bijan Keikhaei, Riitta Lassila, MD PR, Frank W.G. Leebeek, MD PhD, Maria Fernanda Lopez Fernandez, Pier Mannuccio Mannucci, MD, Maria Gabriella Mazzucconi, MD, Massimo Morfini, MD, Nikolas Nikšić, Johannes Oldenburg, Florian Oyen, Rafael Parra Lòpez, Ian Peake, PhD, Gholamreza Toogeh, Alberto Tosetto, Marc Trossaert, Sayed Omid Reza Zekavat, MD, Eva M.K. Zetterberg, MD PhD, Augusto B Federici, MD

Blood (2018) 132 (Supplement 1): 1184.

https://doi.org/10.1182/blood-2018-99-114702

Published: 2018

Journal Articles

Renal Status and Hematuria in Older Patients with Hemophilia

Pal André Holme, PhDMD, Robert Campbell Tait, MD, Christophe Combescure, PhD, Erik Berntorp, MD PhD, Annarita Tagliaferri, Peter Staritz, MD, Roger E.G. Schutgens, MD PhD, Robert Klamroth, Natascha Marquardt, Stephan Rauchensteiner, Philippe De Moerloose, MD PhD

Blood (2015) 126 (23): 2290.

https://doi.org/10.1182/blood.V126.23.2290.2290

Published: 2015

Journal Articles

Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A

Erik Berntorp, Alfonso Iorio

Blood (2015) 125 (24): 3816–3817.

https://doi.org/10.1182/blood-2014-10-608471

Published: 2015

Journal Articles

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Gerald Spotts, PhD, Steven W. Pipe, MD, Erik Berntorp, MD PhD, Peter W. Collins, MD, Victor S. Blanchette, MD FRCPC, Kathelijn Fischer, MD PhD MSC, MyungShin Oh, Leonard A. Valentino, MD FAAP

Blood (2014) 124 (21): 689.

https://doi.org/10.1182/blood.V124.21.689.689

Published: 2014

Journal Articles

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s

Kathelijn Fischer, Katarina Steen Carlsson, Pia Petrini, Margareta Holmström, Rolf Ljung, H. Marijke van den Berg, Erik Berntorp

Blood (2013) 122 (7): 1129–1136.

https://doi.org/10.1182/blood-2012-12-470898

Published: 2013

Includes: Supplemental data

Journal Articles

The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

Jan Astermark, Sharyne M. Donfield, Edward D. Gomperts, John Schwarz, Erika D. Menius, Anna Pavlova, Johannes Oldenburg, Bailey Kessing, Donna M. DiMichele, Amy D. Shapiro, Cheryl A. Winkler, Erik Berntorp

Blood (2013) 121 (8): 1446–1454.

https://doi.org/10.1182/blood-2012-06-434803

Published: 2013

Includes: Supplemental data

Journal Articles

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Pablo Rendo, MD, Erik Berntorp, MD, PhD, David M. Keeling, MD, Michael Makris, MD, Cedric R. Hermans, MD., PhD., Ereline Pauline Mauser-Bunschosten, Roberto Musso, Annarita Tagliaferri, Carl Kollmer, James Baumann, Robert Charnigo

Blood (2010) 116 (21): 3664.

https://doi.org/10.1182/blood.V116.21.3664.3664

Published: 2010

Journal Articles

Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease: Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group

Erik Berntorp, MD, PhD, Thomas C. Abshire, MD, Augusto B. Federici, MD

Blood (2010) 116 (21): 236.

https://doi.org/10.1182/blood.V116.21.236.236

Published: 2010

Journal Articles

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Jan Astermark, MD, PhD, John Schwarz, MA, Sharyne M. Donfield, PhD, Donna M. DiMichele, MD, Bruce M. Ewenstein, MD, PhD, Edward D. Gomperts, MD, George W. Nelson, PhD, Johannes Oldenburg, MD, PhD, Amy D. Shapiro, MD, Gerald Spotts, PhD, Cheryl A. Winkler, PhD, Erik Berntorp, MD, PhD

Blood (2009) 114 (22): 217.

https://doi.org/10.1182/blood.V114.22.217.217

Published: 2009

Journal Articles

Delays in maturation among adolescents with hemophilia and a history of inhibitors

Sharyne M. Donfield, Henry S. Lynn, Alice E. Lail, W. Keith Hoots, Erik Berntorp, Edward D. Gomperts

Blood (2007) 110 (10): 3656–3661.

https://doi.org/10.1182/blood-2007-05-088062

Published: 2007

Includes: Supplemental data

Journal Articles

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A

Jan Astermark, Johannes Oldenburg, Joyce Carlson, Anna Pavlova, Kaan Kavakli, Erik Berntorp, Ann-Kari Lefvert, for the MIBS Study Group

Blood (2006) 108 (12): 3739–3745.

https://doi.org/10.1182/blood-2006-05-024711

Published: 2006

Journal Articles

Association between a History of Inhibitors and Delays in Skeletal Maturation in Adolescents with Hemophilia.

Sharyne M. Donfield, PhD, Alice Lail, M.P.H., Edward D. Gomperts, M.D., W. Keith Hoots, M.D., Erik Berntorp, M.D., Ph.D., Henry S. Lynn, Ph.D.

Blood (2006) 108 (11): 1022.

https://doi.org/10.1182/blood.V108.11.1022.1022

Published: 2006

Journal Articles

Health-Economic Analysis of Alternative Bypassing Agents in Haemophilia Complicated by an Inhibitor - the FEIBA® NovoSeven® Comparative Study (FENOC).

Katarina Steen Carlsson, PhD, Jan Astermark, PhD, MD, Sharyne M. Donfield, PhD, Erik Berntorp, MD

Blood (2006) 108 (11): 457.

https://doi.org/10.1182/blood.V108.11.457.457

Published: 2006

Journal Articles

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

Jan Astermark, Sharyne M. Donfield, Donna M. DiMichele, Alessandro Gringeri, Steven A. Gilbert, Jennifer Waters, Erik Berntorp, for the FENOC Study Group

Blood (2006) 109 (2): 546–551.

https://doi.org/10.1182/blood-2006-04-017988

Published: 2006

Journal Articles

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A

Jan Astermark, Johannes Oldenburg, Anna Pavlova, Erik Berntorp, Ann-Kari Lefvert, for the MIBS Study Group

Blood (2006) 107 (8): 3167–3172.

https://doi.org/10.1182/blood-2005-09-3918

Published: 2006

NARROW

Immune tolerance induction in development

Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI)

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Renal Status and Hematuria in Older Patients with Hemophilia

Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s

The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease: Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Delays in maturation among adolescents with hemophilia and a history of inhibitors

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A

Association between a History of Inhibitors and Delays in Skeletal Maturation in Adolescents with Hemophilia.

Health-Economic Analysis of Alternative Bypassing Agents in Haemophilia Complicated by an Inhibitor - the FEIBA® NovoSeven® Comparative Study (FENOC).

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only